JPRN-jRCT2080221922已完成3 期
Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 346
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
排除标准
- •Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma
研究者
相似试验
进行中（未招募）
1 期
Study of a new drug combination for the treatment of Non Hodgkin’s LymphomaEUCTR2008-004177-17-GBovartis Pharma Services AG346
进行中（未招募）
1 期
A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of TreatmentEUCTR2008-004177-17-GRGlaxoSmithKline Research and Development Limited376
进行中（未招募）
1 期
Study of a new drug combination for the treatment of Non Hodgkin’s LymphomaIndolent B-cell Non-Hodgkin’s LymphomaMedDRA version: 18.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2008-004177-17-BEGlaxoSmithKline Research and Development Limited346
进行中（未招募）
1 期
Study of a new drug combination for the treatment of Non Hodgkin’s LymphomaEUCTR2008-004177-17-SKovartis Pharma Services AG346
进行中（未招募）
1 期
A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment - COMPLEMENT A + BIndolent B-cell Non-Hodgkin’s LymphomaMedDRA version: 9.1Level: LLTClassification code 10029547EUCTR2008-004177-17-ITGlaxoSmithKline Research & Development Ltd346